TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Aardvark Therapeutics, Inc. ( (AARD) ) has provided an announcement.
On September 2, 2025, Aardvark Therapeutics, Inc. updated its corporate presentation, highlighting its strategic focus on treating rare metabolic diseases and obesity with novel therapies. The company is advancing its ARD-101 and ARD-201 programs, with the HERO trial for Prader-Willi Syndrome in Phase 3 and expected data readout in Q3 2026, positioning itself to address significant market opportunities and unmet medical needs.
The most recent analyst rating on (AARD) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Aardvark Therapeutics, Inc. stock, see the AARD Stock Forecast page.
Spark’s Take on AARD Stock
According to Spark, TipRanks’ AI Analyst, AARD is a Underperform.
Aardvark Therapeutics, Inc. faces severe financial challenges typical of early-stage pharmaceutical companies, with zero revenue and substantial operational losses. The lack of technical and valuation indicators further contributes to the high-risk profile.
To see Spark’s full report on AARD stock, click here.
More about Aardvark Therapeutics, Inc.
Aardvark Therapeutics, Inc. operates in the biopharmaceutical industry, focusing on developing treatments for rare metabolic diseases and obesity. The company is working on innovative therapies such as ARD-101, targeting hyperphagia in Prader-Willi Syndrome, and ARD-201 for obesity, aiming to address significant unmet medical needs in these areas.
Average Trading Volume: 66,419
Technical Sentiment Signal: Strong Sell
Current Market Cap: $180.1M
See more data about AARD stock on TipRanks’ Stock Analysis page.